# A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

> **NCT04574869** · PHASE1 · WITHDRAWN · sponsor: **ReAlta Life Sciences, Inc.**

## Conditions studied

- Acute Lung Injury
- ALI
- COVID-19

## Interventions

- **DRUG:** RLS-0071 10 mg/kg
- **DRUG:** RLS-0071 40 mg/kg
- **DRUG:** Placebo
- **DRUG:** RLS-0071 10 mg/kg
- **DRUG:** RLS-0071 40 mg/kg

## Key facts

- **NCT ID:** NCT04574869
- **Lead sponsor:** ReAlta Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01
- **Primary completion:** 2022-09
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low probability of enrolling patients prior to expiry of study drug.
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574869, "A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04574869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*